Previous 10 | Next 10 |
home / stock / esalf / esalf news
Biogen (BIIB) and Eisai (ESALF) are doing their best to get FDA approval for their Alzheimer's drug aducanumab. However, a closer look at the numbers demonstrates the limited effectiveness of the drug. These numbers further suggest that the current flurry of excitement over aducanumab should b...
Eisai Co., Ltd. (ESALF) Q2 2019 Earnings Conference Call October 30, 2019 3:00 AM ET Company Participants Conference Call Participants Presentation Unidentified Company Representative [Call Starts Abruptly] Now, I would like to explain the consolidated financial results f...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2019 Q2 earnings Read more ...
TOKYO, Oct 23, 2019 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's ...
Deals and Financings Taimei Technology, a Shanghai-Jiaxing SAAS company, completed a $212 million Series E/E+ round to advance its cloud AI-based suite of clinical trial programs. The company says its platform enables clinical research collaboration between sponsors, sites, CROs, patients,...
TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment...
TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kina...
TOKYO, Sept 30, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. The Chinese pharmaceutical market is the second largest market in the world after the United States...
TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia. Under this agreement, the following initiatives are s...
TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. The Coroban predicts inpatients' tumbling and falling risks in advance an...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...